ESSA Pharma
EPIX

$5.38

6.27%

Market Cap: $239M

About: ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.

Employees: 50

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1,125% more call options, than puts

Call options by funds: $245K | Put options by funds: $20K

6% less funds holding

Funds holding: 33 [Q1] → 31 (-2) [Q2]

9.27% less ownership

Funds ownership: 88.64% [Q1] → 79.37% (-9.27%) [Q2]

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

44% less capital invested

Capital invested by funds: $333M [Q1] → $185M (-$148M) [Q2]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for EPIX.

See Analyst Rankings

Financial journalist opinion

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations well beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Aug. 5, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2024. "With continued focus on execution, we are progressing towards a stream of significant milestones throughout the next nine to twelve months, with the first being the presentation at ESMO of more mature durability data from the Phase 1 dose escalation study evaluating masofaniten combined with enzalutamide in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens," said David Parkinson, MD, President and CEO of ESSA.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

ESSA Pharma to Present at the JonesHealthcare Seaside Summit

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will present at the JonesHealthcare Seaside Summit on Monday, July 15, 2024 at 11:00 a.m.

ESSA Pharma to Present at the JonesHealthcare Seaside Summit

ESSA Pharma to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m.

ESSA Pharma to Present at the Jefferies Global Healthcare Conference

ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer

ESSA Pharma Inc. is developing Masofaniten, a drug that disrupts the androgen receptor to stop prostate cancer growth, with promising results in phase 1 trials. Masofaniten has the potential to overcome resistance to other standard-of-care treatments, offering a more effective option for patients with resistant prostate cancer. The market opportunity for Masofaniten is substantial, with the antiandrogen therapy market generating approximately $9 billion in 2022.

ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 2:30 p.m.

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA , March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R.

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET. David.

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023 Head-to-head Phase 2 dose expansion underway evaluating masofaniten (EPI-7386)/enzalutamide combination versus enzalutamide monotherapy in patients with mCRPC SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Dec. 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023. "We are pleased with the progress made in 2023 with masofaniten (EPI-7386), our first-in-class N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer, which culminated recently in the presentation of Phase 1 dose escalation data at two medical meetings where we showed that the combination of masofaniten with enzalutamide was well-tolerated and demonstrated deep and durable reductions in prostate-specific antigen ("PSA") in patients with metastatic castration-resistant prostate cancer ("mCRPC")," said David Parkinson, MD, President and CEO of ESSA.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

See News Rankings